About Transgene
Transgene is a publicly listed company based in Illkirch-graffenstaden (France) founded in 1979. Therapeutic vaccines for cancer and infectious diseases are developed. It operates on a HealthTech model. The company has 165 employees. Transgene offers products and services including TG4050, TG4001, TG6050, and BT-001. Its focus areas include Biotechnology and Cancer Immunotherapy. Its legal entity is Transgene SA.
Company details
Immunotherapies targeting cancer are designed and developed by Transgene. Focus is placed on therapeutic vaccines and oncolytic viruses. Platforms like myvac and Invir.IO are utilized for personalized and advanced treatments. The healthcare sector, specifically cancer immunotherapy, is primarily served. Solutions are created through genetic engineering and artificial intelligence. Collaboration with international partners and multidisciplinary teams is maintained. Clinical trials and research updates are regularly published.
- Headquarters Illkirch-graffenstaden, France
- Employees 165
- Stage Public
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Phone•••• ••••
- Website transgene.fr
- Social LinkedIn X
- Legal Name Transgene Sa
- Annual Revenue$160.98 K (USD)291.43as on Dec 31, 2025
- Net Profit-$44.09 M (USD)-10.46as on Dec 31, 2025
- EBITDA-$46.61 M (USD)2.41as on Dec 31, 2025
- Latest Funding Round$22.65M (USD), Debt – Conventional
Mar 2019
- Investors
- Employee Count165
Products & Services of Transgene
Transgene offers a comprehensive portfolio of products and services, including TG4050, TG4001, TG6050, and BT-001.
Individualized vaccine developed for cancer using AI technology.
Vaccine designed for cancer with shared antigen targets.
Vaccine created for cancer immunotherapy with specific targets.
Oncolytic virus engineered to attack cancer tumor cells.
Funding Insights of Transgene
- Total Rounds 4
- Last Round Debt – Conventional — $22.65M
- First Round $186M
(Jun 2010)
- Investors Count 1
All 4 funding rounds of Transgene with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Mar 2019 | $22.65M | Debt – Conventional | – | – | |
| Nov 2017 | $16.73M | Post-IPO | – | – | – |
| Mar 2014 | $27.59M | Post-IPO | – | – | – |
| Jun 2010 | $186M | Post-IPO | – | – | – |
1 investors in total: 1 institutional.
Investors in Transgene
Transgene has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Natixis.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Multi-disciplinary global financial services provider | 2006 | natixis.com | Paris, France |
Investor details for Transgene
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Transgene
39 people are tracked at Transgene (15 in leadership, 10 in board & advisors, 14 in team); the tracked headcount is 165.
| Name | Role | Group |
|---|---|---|
Simone Steiner | Chief Technical Officer | Leadership |
Katell Bidet Huang | Head Of Translational Medicine | Leadership |
Maurizio Ceppi | Chief Scientific Officer (cso) | Leadership |
James Wentworth | VP & Chief Business Officer | Leadership |
John Felitti | VP, General Counsel & Corporate Secretary | Leadership |
Gaëlle Stadtler | VP, Human Resources Director | Leadership |
Clementine Spring-Giusti | Head Of Toxicology | Leadership |
Maud Brandely Talbot | VP Medical and Regulatory Affairs, Chief Medical Officer | Leadership |
Alessandro Riva | Chairman & CEO | Leadership |
Jean-Marc Balloul | Director Innovation & Partnership | Leadership |
Berangere Bastien | Head Of Biometry (biostatistics, Data Management) | Leadership |
Gisele Lacoste | Clinical Scientist / Associate Medical Director | Leadership |
Nathalie Silvestre | Head Of Vectorology Laboratory | Leadership |
Karine Lugardon | Head Of Program Management | Leadership |
J-B Marchand | Head Of Protein Science Lab | Leadership |
John C. Bell | Advisor | Board & advisors |
Pedro Romero | Advisor | Board & advisors |
Marie Landel | Independent Director | Board & advisors |
Jean-Luc Bélingard | Director | Board & advisors |
Carol Stuckley | Independent Director | Board & advisors |
19 more people are available in the full profile.
Complete people profiles for Transgene
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Transgene
Transgene is a publicly listed company on the EURONEXT with ticker symbol TNG in France, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date27 Mar 1998
- Listed onEuronext: TNG
- Listed entityTransgene SA
- Exchange sectorHealth technology
- ISINFR0005175080
- Share price0.69 EUR (-0.29% on the day) · 2026-10-14
- Market capitalisation192,847,304.00 EUR
- EPS (diluted, trailing year)-0.17 EUR
- Volume (last session)26,279
Financials of Transgene
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | 137,000 EUR | -37.5M EUR | -39.7M EUR |
| 2024 | 35,000 EUR | -34.0M EUR | -40.6M EUR |
| 2023 | 1.2M EUR | -22.3M EUR | -33.8M EUR |
| 2022 | 3.1M EUR | -32.8M EUR | -35.3M EUR |
| 2021 | 10.0M EUR | -19.5M EUR | -27.8M EUR |
Detailed financial statements for Transgene
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Transgene
4 dated milestones of Transgene across 40 years, from founding to its latest funding, stage changes and deals.
- Founded Transgene is founded.
- IPO Lists on the stock exchange (IPO).
- Funding First funding round of $186.0M.
- Funding Latest funding round, Debt – Conventional, of $22.6M.
Web traffic of Transgene
The website of Transgene (transgene.fr) receives about 6.8K visits a month and ranks #2,711,242 among all websites worldwide, #3,668 in Biotechnology and Pharmaceuticals.
- Monthly visits6.8K
▼ 11.3% vs previous month
- Unique visitors3.1K
per month
- Global rank#2,711,242
among all websites
- Category rank#3,668
Health · Biotechnology and Pharmaceuticals
- Bounce rate34%
- Pages per visit1.8
- Average visit22 sec
- DevicesDesktop 26% · Mobile 74%
Websites whose visitors overlap most with Transgene. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| inovio.com | 100% | 11.7K | #1,670,423 | View details | |
| amgen.com | 91% | 495.4K | #116,434 | View details | |
| genzyme.com | 83% | View details | |||
| gsk.com | 79% | 1.3M | #56,834 | View details | |
| genvec.com | 75% | View details | |||
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 11 similar websites and full traffic analytics for Transgene
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 11 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Transgene
Complete news archive for Transgene
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Transgene
Transgene was founded in 1979 and raised its 1st funding round 31 years after it was founded.
Transgene is headquartered in Illkirch-graffenstaden, France. It is registered at Illkirch-graffenstaden, Bas-rhin, France.
Transgene has 165 employees.
Annual revenue of Transgene is $160.98K as on Dec 31, 2025.
Immunotherapies targeting cancer are designed and developed by Transgene. Focus is placed on therapeutic vaccines and oncolytic viruses. Platforms like myvac and Invir.IO are utilized for personalized and advanced treatments. The healthcare sector, specifically cancer immunotherapy, is primarily served. Solutions are created through genetic engineering and artificial intelligence. Collaboration with international partners and multidisciplinary teams is maintained. Clinical trials and research updates are regularly published.
Transgene offers TG4050, TG4001, TG6050, and BT-001.
Yes, Transgene is publicly traded on EURONEXT under the ticker symbol TNG.
Transgene has 1 investor. Key investors include Natixis.
Transgene operates through Transgene Sa.